https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-10 08:39:442024-12-10 08:39:44Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-10 08:39:442024-12-10 08:39:44Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-09 08:23:212024-12-09 08:23:21Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-05 12:30:092024-12-05 12:30:09NICE Recommends ublituximab (BRIUMVI®▼) as an Option for Treating Relapsing-Remitting Multiple Sclerosis (RRMS)
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-05 08:42:342024-12-05 08:42:34Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synaffix_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-04 08:38:562025-01-20 10:30:25Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
https://www.optimumcomms.com/wp-content/uploads/2024/12/Antag_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-04 08:29:572024-12-04 08:43:14Antag Therapeutics Announces €80 Million Series A Financing
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-25 09:51:202024-11-25 09:51:20Novo Holdings to acquire Benchmark Genetics, a leader in aquaculture genetics
https://www.optimumcomms.com/wp-content/uploads/2024/09/Vicebio_Logo_300x180px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-21 08:43:182024-11-21 08:46:15Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-20 08:38:452024-11-20 08:38:45Poolbeg Pharma plc – POLB 001 Patent Granted in United States
https://www.optimumcomms.com/wp-content/uploads/2024/11/Freya_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-19 12:00:372024-11-19 12:09:58Women’s Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-19 08:36:022024-11-19 08:36:02Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-18 20:00:032024-11-19 11:54:33Denmark’s new AI supercomputer Gefion ranks 21 on the world’s TOP500 list
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-18 08:40:092024-11-18 08:40:09BrightHeart Secures FDA Clearance for First AI Software Revolutionizing Prenatal Fetal Heart Ultrasound Evaluations
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-18 08:38:182024-11-18 08:38:18Cure51 launches NHS-approved study with Cambridge University Hospitals and seven other leading UK oncology institutions to unlock cancer survival secrets
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-14 14:55:252024-11-14 14:55:25Neuraxpharm reports another year of sustained growth and international expansion
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-11-14 10:06:502024-11-15 10:11:10Vivet Therapeutics to Present Key Findings on its Gene Therapy Program forCerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual MeetingWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
